8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): December 1, 2009

BIOSPECIFICS TECHNOLOGIES CORP.
(Exact name of registrant as specified in its charter)

Delaware	0-19879	11-3054851
(State or Other Jurisdiction	(Commission File Number)	(I.R.S. Employer
Of Incorporation)		Identification No.)

35 Wilbur Street
Lynbrook, NY 11563
(Address of Principal Executive Office) (Zip Code)

516.593.7000
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

INTRODUCTORY COMMENT

Throughout this Current Report on Form 8-K, the terms “we,” “us,” “our” and “Company” refer to BioSpecifics Technologies Corp.

ITEM 7.01

REGULATION FD DISCLOSURE

Our President, Thomas L. Wegman, will present to various investors in December 2009.  A copy of the presentation materials is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.  Mr. Wegman is scheduled to give this presentation, for the first time, at the Piper Jaffray 21st Annual Health Care Conference on Tuesday, December 1, 2009, at 3:30 p.m. ET at the New York Palace Hotel in New York, NY.

ITEM 9.01

FINANCIAL STATEMENTS AND EXHIBITS

(d)	Exhibits
99.1	Presentation materials to be used by Thomas L. Wegman, the Company’s President, in December 2009

SIGNATURES

            Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

Date: December 1, 2009	BIOSPECIFICS TECHNOLOGIES CORP.
	——————————————————
	(Registrant)
	/s/ Thomas L. Wegman
	——————————————————
	Thomas L. Wegman
	President

 

EXHIBIT INDEX

Exhibit No.	Description
99.1	Presentation materials to be used by Thomas L. Wegman, the Company’s President, in December 2009

EX-99.1

Exhibit 99.1